324 related articles for article (PubMed ID: 17335681)
1. Chelation therapy for iron overload.
Barton JC
Curr Gastroenterol Rep; 2007 Mar; 9(1):74-82. PubMed ID: 17335681
[TBL] [Abstract][Full Text] [Related]
2. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
4. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
5. [Iron chelating therapy in adults: How and when ?].
Ruivard M
Rev Med Interne; 2013 Jan; 34(1):32-8. PubMed ID: 23195912
[TBL] [Abstract][Full Text] [Related]
6. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Bova C; Filippelli G; Capodanno I; Neri A; Morabito F; Gentile M; Vigna E
Eur J Haematol; 2023 May; 110(5):490-497. PubMed ID: 36708354
[TBL] [Abstract][Full Text] [Related]
8. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
10. Current status of iron overload and chelation with deferasirox.
Choudhry VP; Naithani R
Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
[TBL] [Abstract][Full Text] [Related]
11. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Kolnagou A; Kontoghiorghes GJ
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
[TBL] [Abstract][Full Text] [Related]
12. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox (Exjade) for the treatment of iron overload.
Cappellini MD; Taher A
Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
[TBL] [Abstract][Full Text] [Related]
14. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
Voskaridou E; Christoulas D; Terpos E
Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
[No Abstract] [Full Text] [Related]
15. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
16. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
Forni GL; Kattamis A; Kuo KHM; Maggio A; Sheth S; Taher AT; Viprakasit V
Pediatr Blood Cancer; 2024 Aug; 71(8):e31035. PubMed ID: 38753107
[TBL] [Abstract][Full Text] [Related]
17. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
18. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
19. Iron-chelating therapy for transfusional iron overload.
Brittenham GM
N Engl J Med; 2011 Jan; 364(2):146-56. PubMed ID: 21226580
[TBL] [Abstract][Full Text] [Related]
20. How I treat transfusional iron overload.
Hoffbrand AV; Taher A; Cappellini MD
Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]